The indirect costs of multiple sclerosis: systematic review and meta-analysis
- 18 July 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 15 (5) , 759-786
Abstract
(2015). The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research: Vol. 15, No. 5, pp. 759-786. doi: 10.1586/14737167.2015.1067141Keywords
This publication has 63 references indexed in Scilit:
- Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregiversJournal of the Neurological Sciences, 2013
- Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatmentsDARU Journal of Pharmaceutical Sciences, 2013
- Impact of Mobility Impairment on Indirect Costs and Health-Related Quality of Life in Multiple SclerosisPLOS ONE, 2013
- Burden of a Multiple Sclerosis RelapseThe Patient - Patient-Centered Outcomes Research, 2012
- Cost-effectiveness of disease-modifying therapy for multiple sclerosisNeurology, 2011
- The cost of multiple sclerosis in NorwayThe European Journal of Health Economics, 2010
- The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the USPharmacoEconomics, 2009
- Multiple Sclerosis in the UKPharmacoEconomics, 2008
- The Economics of Multiple SclerosisPharmacoEconomics, 1999
- The Economic Cost of Multiple Sclerosis in Sweden in 1994PharmacoEconomics, 1998